Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma
Germline cancer-predisposition variants (CPVs) can be helpful in predicting risk in some pediatric cancers. However, CPV risk association in children with rhabdomyosarcoma, a cancer of soft tissue such as muscle, tendon, cartilage or bone, has not been well studied. A new report led by researchers at Baylor College of Medicine evaluates the association of germline CPVs with rhabdomyosarcoma outcomes in a cohort of children enrolled in Children’s Oncology Group studies. The findings are published in JAMA Network Open.
“Compared to other pediatric cancers, survival for rhabdomyosarcoma has not improved in recent decades. One limiting factor in clinical practice is the imprecision of risk stratification strategies, which is why we wanted to study whether CPV presence can be used as a measure for high-risk cases,” said corresponding author Dr. Philip Lupo, professor of pediatrics – hematology and oncology and director of the Epidemiology and Population Sciences Program at Texas Children’s Cancer Center.
The researchers analyzed the association between the exome (the protein-coding genes in the genome) and disease outcomes among 580 children with rhabdomyosarcoma. The presence of CPVs in rhabdomyosarcoma-associated genes was associated with more adverse outcomes. Children with embryonal rhabdomyosarcoma and CPVs in the TP53 or HRAS gene had particularly poor outcomes. “These outcomes were not driven by a secondary malignancy, which is an important new finding that is in contrast to current understanding in the field,” said Lupo, a member of the Dan L Duncan Comprehensive Cancer Center at Baylor.
Another important finding identified a group of individuals with CPVs who had not yet been recognized to have poor outcomes. Researchers observed that children with fusion-negative rhabdomyosarcoma and CPVs had comparable outcomes to children with no CPVs and fusion-positive rhabdomyosarcoma, an aggressive subtype known to have poor outcomes.
The results of our study support germline testing for cancer-predisposition variants among children with rhabdomyosarcoma, which could aid in early clinical surveillance strategies for patients and cascade testing of family members,” Lupo said.
“I’m excited that our research might lead to improving clinical guidelines for children diagnosed with rhabdomyosarcoma and their families. I hope that the findings of our paper will result in new discussions about how to improve survival for children diagnosed with cancer,” said first author Dr. Bailey Martin-Giacalone, graduate student in Lupo’s lab at Baylor at the time of research and currently a postdoctoral associate at Washington University in St. Louis.
Other authors of this work are He Li, Michael E. Scheurer, Dana L. Casey, Shannon Dugan-Perez, Deborah A. Marquez-Do, Donna Muzny, Richard A. Gibbs, Donald A. Barkauskas, David Hall, Douglas R. Stewart, Joshua D. Schiffman, Matthew T. McEvoy, Javed Khan, David Malkin, Corinne M. Linardic, Brian D. Crompton, Jack F. Shern, Stephen X. Skapek, Rajkumar Venkatramani, Douglas S. Hawkins, Aniko Sabo and Sharon E. Plon. They are affiliated with one or more of the following institutions: Baylor College of Medicine, Human Genome Sequencing Center at Baylor, University of North Carolina at Chapel Hill, University of Southern California, Children’s Oncology Group, National Cancer Institute, University of Utah, University of Toronto, Duke University, Harvard Medical School, University of Texas Southwestern Medical Center and University of Washington.
This research was supported by the Cancer Prevention and Research Institute of Texas (CPRIT) (RP170071), the National Cancer Institute (U24CA196173, U24CA114766, U10CA098413, U10CA180899, U10CA098543, and U10CA180886), the Children’s Oncology Group Foundation, the QuadW Foundation, the Isabella Santos Foundation, the St. Baldrick’s Foundation, the Intramural Research Programs of the Center for Cancer Research, the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, and the National Human Genome Research Institute (1UM1HG008898). See the publication for a full list of funding sources.
By Molly Chiu
Follow From the Labs on X @BCMFromtheLabs and Instagram!
